



AACR Special Conference in Cancer Research

TUMOR IMMUNOLOGY AND IMMUNOTHERAPY

IN ASSOCIATION WITH THE CANCER IMMUNOLOGY (CIMM) WORKING GROUP
October 18–21, 2024 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research® (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients.

Relationships are abbreviated as follows: E, Employment; FO, Fiduciary Officer; IC, Independent Contractor; S, Stock; SO, Stock Option; OS, Other Securities; OBO, Other Business Ownership; GC, Grant/Contract; T, Travel; GI, Gift; P, Patent; TM, Trademark, C, Copyright; OIP, Other Intellectual Property; O, Other

Last Name	First Name	All Relationships	Type	Role
Arthur	Ronald	No Relationships		Staff
Balachanran	Vinod	No Relationships		Speaker
Bassani-Sternberg	Michal	Merck	IC	Speaker
Belabed	Meriem	No Relationships		Speaker
Chen	Yvonne	Catamaran Bio, Prime Medicine, Waypoint Bio, Pluto Immunotherapeutics, Prime Medicine, AffyImmune, ImmPACT Bio, Notch Therapeutics, Waypoint Bio, Novartis, ImmPACT Bio, Catamaran Bio, Pluto Immunotherapeutics, Sonoma Biotherapeutics, ImmPACT Bio, Notch Therapeutics, Novartis, Sonoma Biotherapeutics	IC, IC, SO, IC, SO, SO, IC, IC, IC, IC, S, SO, SO, SO, SO, SO, IC, IC	Program Committee, Speaker
Cho	Christina	No Relationships		Speaker
Codarri Deak	Laura	F. Hoffmann-La Roche AG, Patent – Inventor of Eciskafusp alfa	E, P	Speaker
De Marco	Lorenzo	Nouscom	E	Speaker
Delgoffe	Greg	Novasenta, Remplir Bio	IC, E	Speaker
Gajewski	Thomas	Bristol Myers Squibb Company, Pyxis Oncology, FogPharma, Jounce Therapeutics, Samyang, Catalym, Bicara, Adaptimmune, Pyxis Oncology, Maia, Allogene, Merck, Pyxis Oncology, Jounce Therapeutics	GC, IC, IC, S, IC, IC, IC, GC, IC, IC, GC, S, IC	Speaker
Gollob	Kenneth	GlaxoSmithKline, Bristol-Myers Squibb	GC, IC	Speaker
Guasp	Pablo	No Relationships		Speaker



AACR Special Conference in Cancer Research

TUMOR IMMUNOLOGY AND IMMUNOTHERAPY

IN ASSOCIATION WITH THE CANCER IMMUNOLOGY (CIMM) WORKING GROUP

October 18-21, 2024 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Hardy	Marie-Pierre	No Relationships		Speaker
Kaeach	Susan	Siren Biotechnology, Simcha Therapeutics, Affini-T Therapeutics, Evolveimmune	IC, IC, SO, IC	Speaker
Krieg	Arthur	Zola Therapeutics, Zola Therapeutics, Zola Therapeutics, Iris Medicines, Korro Bio, Lincswitch, PepGen, Providence Therapeutics, Strand Therapeutics, Switch Therapeutics, Thirona	E, P, S, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, S	Speaker
Levings	Megan	Sangamo	P	Speaker
Lichti	Cheryl	No Relationships		Speaker
Majzner	Robbie	Link Cell Therapies, Lyell, Nkarta, Syncopation	SO, SO, C, SO	
Melief	Cornelis	ISA Pharmaceuticals, ISA Pharmaceuticals	SO, E	Speaker
Merbl	Yifat	Erisyon, Patent, PromiseBio	IC, P, IC	Speaker
Nutt	Sam	No Relationships		Speaker
Quezada	Sergio	achilles therapeutics, achilles therapeutics	E, P	Program Committee, Speaker
Post	Dean	No Relationships		Staff
Ring	Aaron	Seranova Bio, Stipple Bio, Simcha Therapeutics, Seranova Bio, Simcha Therapeutics, Stipple Bio, ALX Oncology, Simcha Therapeutics, Seranova Bio, Simcha Therapeutics, Simcha Therapeutics,	FO, FO, GC, S, P, S, S, S, IC, IC, FO, P, P	Speaker
Scheper	Wouter	BD Biosciences, Lumicks	IC, IC	Speaker
Schreiber	Robert	The University of Texas MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Asher Biotherapeutics, A2 Biotherapeutics, Jounce Therapeutics, Codiak, The Salk Institute for Biological Studies, Arch Oncology, Memorial Sloan-Kettering Cancer Center, John Hopkins University	IC, IC, SO, SO, SO, SO, IC, SO, IC, IC	Program Committee, Speaker
Schumacher	Ton	Scenic Biotech, Celsius, Third Rock Ventures, Celsius, Merus, Merus, Third Rock Ventures, AllogeneTherapeutics, Cell Control, Scenic Biotech, Neogene Therapeutics, AllogeneTherapeutics, Asher Bio, Asher Bio, Neogene Therapeutics	IC, SO, S, IC, IC, SO, IC, IC, S, S, S, SO, IC, S, IC	Speaker

